These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35589126)

  • 1. Naturally Occurring Anti-Idiotypic Antibodies Portray a Largely Private Repertoire in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
    Heeb SR; Schaller M; Kremer Hovinga JA
    J Immunol; 2022 Jun; 208(11):2497-2507. PubMed ID: 35589126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
    Roose E; Vidarsson G; Kangro K; Verhagen OJHM; Mancini I; Desender L; Pareyn I; Vandeputte N; Vandenbulcke A; Vendramin C; Schelpe AS; Voorberg J; Azerad MA; Gilardin L; Scully M; Dierickx D; Deckmyn H; De Meyer SF; Peyvandi F; Vanhoorelbeke K
    Thromb Haemost; 2018 Oct; 118(10):1729-1742. PubMed ID: 30235483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients.
    Schelpe AS; Roose E; Joly BS; Pareyn I; Mancini I; Biganzoli M; Deckmyn H; Voorberg J; Fijnheer R; Peyvandi F; De Meyer SF; Coppo P; Veyradier A; Vanhoorelbeke K
    Haematologica; 2019 Jun; 104(6):1268-1276. PubMed ID: 30523052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura.
    Velásquez Pereira LC; Roose E; Graça NAG; Sinkovits G; Kangro K; Joly BS; Tellier E; Kaplanski G; Falter T; Von Auer C; Rossmann H; Feys HB; Reti M; Prohászka Z; Lämmle B; Voorberg J; Coppo P; Veyradier A; De Meyer SF; Männik A; Vanhoorelbeke K
    J Thromb Haemost; 2021 Feb; 19(2):478-488. PubMed ID: 33171004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura.
    Kangro K; Roose E; Joly BS; Sinkovits G; Falter T; von Auer C; Rossmann H; Reti M; Voorberg J; Prohászka Z; Lämmle B; Coppo P; Veyradier A; De Meyer SF; Männik A; Vanhoorelbeke K
    Blood Adv; 2021 Sep; 5(17):3427-3435. PubMed ID: 34495312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daratumumab for immune thrombotic thrombocytopenic purpura.
    van den Berg J; Kremer Hovinga JA; Pfleger C; Hegemann I; Stehle G; Holbro A; Studt JD
    Blood Adv; 2022 Feb; 6(3):993-997. PubMed ID: 34551063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-mediated thrombotic thrombocytopenic purpura in patients with and without systemic lupus erythematosus: a retrospective study.
    Yue C; Su J; Fan X; Song L; Jiang W; Xia J; Shi T; Zhang X; Li X
    Orphanet J Rare Dis; 2020 Aug; 15(1):225. PubMed ID: 32859237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura.
    Halkidis K; Meng C; Liu S; Mayne L; Siegel DL; Zheng XL
    Blood; 2023 Jun; 141(24):2993-3005. PubMed ID: 37023370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overlapping ADAMTS13 peptide binding profiles of DRB1∗08:03 and DRB1∗11:01 suggest a common etiology of immune-mediated thrombotic thrombocytopenic purpura.
    Sakai K; Miyadera H; Kubo M; Nakajima F; Matsumoto M
    J Thromb Haemost; 2023 Mar; 21(3):616-628. PubMed ID: 36696200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura.
    Luken BM; Kaijen PH; Turenhout EA; Kremer Hovinga JA; van Mourik JA; Fijnheer R; Voorberg J
    J Thromb Haemost; 2006 Nov; 4(11):2355-64. PubMed ID: 16898953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro.
    Ostertag EM; Kacir S; Thiboutot M; Gulendran G; Zheng XL; Cines DB; Siegel DL
    Transfusion; 2016 Jul; 56(7):1763-74. PubMed ID: 27040144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP.
    De Waele L; Curie A; Kangro K; Tellier E; Kaplanski G; Männik A; Tersteeg C; Joly BS; Coppo P; Veyradier A; De Meyer SF; Roose E; Vanhoorelbeke K
    Blood Adv; 2021 Nov; 5(21):4480-4484. PubMed ID: 34559219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.
    Sui J; Cao W; Halkidis K; Abdelgawwad MS; Kocher NK; Guillory B; Williams LA; Gangaraju R; Marques MB; Zheng XL
    Blood Adv; 2019 Dec; 3(24):4177-4186. PubMed ID: 31856267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADAMTS-13 conformation influences autoimmune recognition in immune thrombotic thrombocytopenic purpura.
    Underwood MI; Thomas MR; Scully MA; Crawley JTB
    J Thromb Haemost; 2024 Apr; 22(4):1069-1079. PubMed ID: 38160729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
    Joly BS; Stepanian A; Leblanc T; Hajage D; Chambost H; Harambat J; Fouyssac F; Guigonis V; Leverger G; Ulinski T; Kwon T; Loirat C; Coppo P; Veyradier A;
    Lancet Haematol; 2016 Nov; 3(11):e537-e546. PubMed ID: 27720178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura.
    Sakai K; Matsumoto M; De Waele L; Dekimpe C; Hamada E; Kubo M; Tersteeg C; De Meyer SF; Vanhoorelbeke K
    Blood Adv; 2023 Jan; 7(1):131-140. PubMed ID: 36306339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigen.
    Dekimpe C; Roose E; Tersteeg C; Joly BS; Dewaele A; Horta S; Pareyn I; Vandenbulcke A; Deckmyn H; Feys HB; Tellier E; Kaplanski G; Scully M; Coppo P; De Meyer SF; Veyradier A; Vanhoorelbeke K
    J Thromb Haemost; 2020 Apr; 18(4):985-990. PubMed ID: 31989742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
    Thomas MR; de Groot R; Scully MA; Crawley JT
    EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation and validation of small ADAMTS13 fragments for epitope mapping of anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura.
    Kangro K; Roose E; Schelpe AS; Tellier E; Kaplanski G; Voorberg J; De Meyer SF; Männik A; Vanhoorelbeke K
    Res Pract Thromb Haemost; 2020 Jul; 4(5):918-930. PubMed ID: 32685903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.
    Roose E; Schelpe AS; Tellier E; Sinkovits G; Joly BS; Dekimpe C; Kaplanski G; Le Besnerais M; Mancini I; Falter T; Von Auer C; Feys HB; Reti M; Rossmann H; Vandenbulcke A; Pareyn I; Voorberg J; Greinacher A; Benhamou Y; Deckmyn H; Fijnheer R; Prohászka Z; Peyvandi F; Lämmle B; Coppo P; De Meyer SF; Veyradier A; Vanhoorelbeke K
    Blood; 2020 Jul; 136(3):353-361. PubMed ID: 32356859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.